Department of Endocrinology, Third People's Hospital of Huizhou, Huizhou, China.
Department of Endocrinology, Huizhou Hospital of Guangzhou Medical University, Huizhou, China.
Postgrad Med. 2021 Nov;133(8):860-864. doi: 10.1080/00325481.2021.1917930. Epub 2021 Apr 26.
: The current study was to evaluate risk factors and atherosclerotic cardiovascular disease (ASCVD) among diabetic patients by sex.: Patients with type 2 diabetes mellitus were enrolled, and baseline characteristics and prevalent ASCVD (including coronary heart disease [CHD], ischemic stroke [IS], and peripheral vascular disease [PVD]) were collected and compared by sex.: Females accounted for 48.5% (n = 284) of the current study. Compared to males, females had a longer duration of diabetes mellitus (9.1 ± 4.0 vs 8.0 ± 3.7 years), and were more likely to be obese (38% vs 34.4%), have hypertension (49.3% vs 45.7%) and have a lower estimated glomerular filtration rate (75.0 ± 20.6 vs 77.4 ± 19.2 ml/min/1.73 m). Females were less likely to smoke (2.8% vs 31.1%), and receive anti-platelets (53.5% vs 56%), angiotensin converting enzyme inhibitor/angiotensin receptor blocker (31.7% vs 35.1%), and metformin (81.7% vs 85.4%). Females had a higher prevalence of CHD (9.9% vs 8.6%) and composite ASCVD (21.8% vs 18.9%). After adjustment for potential covariates, female sex remained independently associated with composite ASCVD (odds ratio [OR]: 1.21 and 95% confidence interval [CI]: 1.05-1.57) and CHD (OR: 1.13 and 95% CI: 1.01-1.38).: Among diabetic people, compared to males, females had a higher comorbid burden but received less optimal treatment, which might partly explain their higher prevalence of composite ASCVD and CHD.
本研究旨在评估糖尿病患者的危险因素和动脉粥样硬化性心血管疾病（ASCVD）。
纳入了 2 型糖尿病患者，收集了他们的基线特征和现患 ASCVD（包括冠心病[CHD]、缺血性卒中和外周血管疾病[PVD]），并按性别进行了比较。
在本研究中，女性占 48.5%（n=284）。与男性相比，女性糖尿病病程更长（9.1±4.0 年 vs 8.0±3.7 年），更易肥胖（38% vs 34.4%），高血压（49.3% vs 45.7%）和估算肾小球滤过率较低（75.0±20.6 vs 77.4±19.2 ml/min/1.73 m）。女性吸烟的可能性较小（2.8% vs 31.1%），接受抗血小板药物（53.5% vs 56%）、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂（31.7% vs 35.1%）和二甲双胍（81.7% vs 85.4%）的可能性也较小。女性 CHD（9.9% vs 8.6%）和复合 ASCVD（21.8% vs 18.9%）的患病率较高。在调整了潜在混杂因素后，女性性别与复合 ASCVD（比值比[OR]：1.21，95%置信区间[CI]：1.05-1.57）和 CHD（OR：1.13，95% CI：1.01-1.38）独立相关。
在糖尿病患者中，与男性相比，女性的合并症负担更高，但接受的治疗不够理想，这可能部分解释了她们复合 ASCVD 和 CHD 患病率较高的原因。
